Method for producing adult liver progenitor cells
Novel adult liver progenitor cells (called H2Stem Cells) have been have been characterized on the basis of a series of biological activities and markers. Methods for producing H2Stem Cells allow providing such cells in the form of adherent cells and three-dimensional cell clusters in suspension that can be differentiated into cells having strong liver-specific activities and/or that can be used for treating liver diseases or for evaluating the efficacy, the metabolism, and/or toxicity of a compound.
1. A method of treating a liver condition in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of:
(i) an isolated human adult liver progenitor cell wherein said cell is measured:
(a) positive for a-smooth muscle actin (ASMA), albumin (ALB), and CD140b, and
(b) negative for Sushi domain containing protein 2 (SUSD2) and Cytokeratin-19 (CK-19), or
(ii) an isolated cell population, wherein at least 60% of the cells of the population are cells of (i),
wherein the liver condition may benefit from engraftment of said cells in a human tissue of the subject, and wherein said pharmaceutical composition is administered to said subject via intrahepatic, intrasplenic, or intravenous routes.
2. The method of claim 1 , wherein said cell of (i) is further measured positive for:
(a) At least one hepatic marker selected from the group consisting of albumin, HNF-3B, HNF-4, CYP1A2, CYP2C9, CYP2E1 and CYP3A4;
(b) At least one mesenchymal marker selected from the group consisting of Vimentin, CD90, CD73, CD44, and CD29;
(c) At least one liver-specific activity selected from the group consisting of urea secretion, bilirubin conjugation, alpha-1-antitrypsin secretion, and CYP3A4 activity;
(d) At least one marker selected from the group consisting of ATP2B4, ITGA3, TFRC, SLC3A2, CD59, ITGB5, CD151, ICAM1, ANPEP, CD46, and CD81; and
(e) At least one marker selected from the group consisting of MMP1, ITGA11, FMOD, KCND2, CCL11, ASPN, KCNK2, and HMCN1.
3. The method of claim 1 characterized in that the cell of (i) is measured negative for:
(a) CD271;
(b) At least one marker selected from the group consisting of ITGAM, ITGAX, IL1R2, CDH5, and NCAM1; and
(c) At least one marker selected from the group consisting of HP, CP, RBP4, APOB, LBP, ORM1, CD24, CPM, and APOC1.
4. The method of claim 1 , wherein said cell of (i) is further measured positive for at least one liver-specific activity selected from the group consisting of sulfotransferase activity, tryptophan-2,3-dioxygenase activity, liver carboxylase activity, ammonia metabolism, and glycogen storage.
5. The method of claim 1 , wherein the isolated cell population comprises between 60% and 99% of said cells of (i).
6. The method of claim 1 , wherein the isolated cell population comprises between 70% and 90% of said cells of (i).
7. The method of claim 6 , wherein said cells of (i) in said cell population are further differentiated into cells presenting liver-specific activities.
8. The method of claim 1 , wherein said cell of (i) or population of (ii) is further modified by means of one or more chemical agents, cell culture medium, growth factors, and/or nucleic acid vectors.
9. The method of claim 1 , wherein the liver condition is a liver disease selected from the group consisting of an inborn error of liver metabolism, an inherited Blood Coagulation Disorder, progressive familial intrahepatic cholestasis type 1/2/3, alpha 1-Antitrypsin Deficiency, defect of liver cell transporters, Porphyria , fatty liver or fibrotic liver disease, primary biliary cirrhosis, sclerosing cholangitis, liver degenerative disease, and acute or chronic liver failure.
10. The method of claim 1 , wherein the subject is a human.